Thumbnail Image
Publication

Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.

Ryom, Lene
; 
De Miguel, Rosa
; 
Cotter, Aoife Grace
; 
Podlekareva, Daria
; 
Beguelin, Charles
; 
Waalewijn, Hylke
; 
Arribas, JosĆØ R
; 
Mallon, Patrick W G
; 
Marzolini, Catia
; 
Kirk, Ole
... show 10 more
Author
Ryom, Lene
 De Miguel, Rosa
 Cotter, Aoife Grace
 Podlekareva, Daria
 Beguelin, Charles
 Waalewijn, Hylke
 Arribas, JosĆØ R
 Mallon, Patrick W G
 Marzolini, Catia
 Kirk, Ole
 Bamford, Alasdair
 Rauch, Andri
 Molina, Jean Michel
 Kowalska, Justyna Dominika
 Guaraldi, Giovanni
 Winston, Alan
 Boesecke, Christoph
 Cinque, Paola
 Welch, Steven
 Collins, Simon
 Behrens, Georg M N
Advisors
Editors
Other Contributors
Departments
Date
2022-03-25
Date Submitted
Keywords
COVID-19
European AIDS Clinical Society (EACS) Guidelines
HIV
Penta
antiretroviral treatment
children
comorbidities
drug-drug interactions
hepatitis B virus
hepatitis C virus
opportunistic infections
Other Subjects
Subject Mesh
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Thumbnail Image
HIV-23-849.pdf
Adobe PDF, 235.91 KB
Alternative Titles
Publisher
URI
https://hdl.handle.net/10147/646636
Abstract
BACKGROUND: The European AIDS Clinical Society (EACS) Guidelines were revised in 2021 for the 17th time with updates on all aspects of HIV care. KEY POINTS OF THE GUIDELINES UPDATE: Version 11.0 of the Guidelines recommend six first-line treatment options for antiretroviral treatment (ART)-naĆÆve adults: tenofovir-based backbone plus an unboosted integrase inhibitor or plus doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. Recommendations on preferred and alternative first-line combinations from birth to adolescence were included in the new paediatric section made with Penta. Long-acting cabotegravir plus rilpivirine was included as a switch option and, along with fostemsavir, was added to all drug-drug interaction (DDI) tables. Four new DDI tables for anti-tuberculosis drugs, anxiolytics, hormone replacement therapy and COVID-19 therapies were introduced, as well as guidance on screening and management of anxiety disorders, transgender health, sexual health for women and menopause. The sections on frailty, obesity and cancer were expanded, and recommendations for the management of people with diabetes and cardiovascular disease risk were revised extensively. Treatment of recently acquired hepatitis C is recommended with ongoing risk behaviour to reduce transmission. Bulevirtide was included as a treatment option for the hepatitis Delta virus. Drug-resistant tuberculosis guidance was adjusted in accordance with the 2020 World Health Organization recommendations. Finally, there is new guidance on COVID-19 management with a focus on continuance of HIV care. CONCLUSIONS: In 2021, the EACS Guidelines were updated extensively and broadened to include new sections. The recommendations are available as a free app, in interactive web format and as an online pdf.
Language
en
Citation
ISSN
1468-1293
eISSN
ISBN
DOI
10.1111/hiv.13268
PMID
35338549
PMCID
Sponsorships
Funding Sources
Funding Amounts
Grant Identifiers
Methodology
Duration
Ethical Approval